Introduction
Malaria is a severe disease that ranks among the most prevalent infections in tropical areas throughout the world. Approximately 250-300 million people become infected yearly with relatively high rates of morbidity and mortality. The WHO estimates that every year nearly one million children die of malaria in Africa alone [1] . The widespread occurrence and the increasing incidence of malaria in many countries, caused by drug resistant parasites and insecticide resistant vectors (Anopheles mosquitoes), underscore the need for developing new methods of controlling this disease, which include more effective vaccines.
Most vaccine efforts are directed against the preerythrocytic stages (sporozoites (Spz) and liver stages) and blood stages [2] . The finding that vaccination with radiationattenuated sporozoites (IrSpz) can induce complete protection (i.e., sterile immunity) against malaria infection not only in experimental animals but also in man [3] [4] [5] [6] [7] demonstrated the feasibility of effective vaccination against this disease. A number of mouse studies to date using Plasmodium yoelii and P. berghei parasites for challenge have shown that protective immunity against preerythrocytic stages is mediated in part by T cells, particularly CD8+ T cells. Firstly, the major role for CD8+ T cells was shown by studies in which in vivo depletion of CD8+ T cells abrogated Spz-induced protective immunity in mice [8, 9] . Secondly, the adoptive transfer of CD8+ T-cell clones specific for the immunodominant CD8+ T-cell epitope, SYVPSAEQI, of the P. yoelii circumsporozoite (PyCS) protein, a major Spz antigen, confers protection 2 Mediators of Inflammation against Spz challenge in naïve mice [10, 11] . More recently, by using transgenic (Tg) mice expressing a T-cell receptor (TCR), based on the TCR sequence of CD8+ T cells recognizing the SYVPSAEQI epitope, transgenic CD8+ T cells were shown to mediate protection against malaria [12] . Finally, Hoffman's group has recently shown that intravenous (IV) immunization of IrSpz vaccine is very effective in inducing a high frequency of malaria-specific CD8+ T cells in the liver of nonhuman primates and mice and, furthermore, conferring protection in mice [13] . More recently the same group showed that immunization of multiple doses of their IrPfSPZ vaccine by IV conferred protection in six out of six vaccines against malaria challenge [14] .
Thus, a number of studies have shown that CD8+ T cells can significantly contribute to the protective immunity against the liver stages of malaria parasites in mice [8] [9] [10] [11] [12] [13] [14] [15] [16] 
Materials and Methods

2.1.
Mice. B6 mice and BALB/c mice were purchased from the Jackson Laboratory (Bar Harbor, ME). Transgenic mice
mice under the control of the H-2K b promoter on the B6 background were derived as previously described [17] . CS transgenic mice expressing CS gene of P. yoelii (17X NL) on the B6 background, CS-Tg mice [18] , were kindly provided to us by Dr. Victor Nussenzweig at New York University. (MHC-I-K d -Tg × CS-Tg) F1 mice were generated by crossing CS-Tg mice to MHC-I-K d -Tg mice.
Antibodies. The following monoclonal antibodies (mAb)
were purchased from BioLegend (San Diego, CA) and 
Flow Cytometric Analysis.
Murine cells were incubated with unlabeled anti-CD16/CD32 mAb for 10 min at RT and later incubated with the respective mAbs described in the preceding section. All cells were costained with propidium iodide (Sigma-Aldrich, St. Louis, MO) to exclude nonviable cells. Flow cytometric data collection was performed using an LSR II Flow Cytometer (BD Biosciences, San Jose, CA). Subsequent data analyses were performed using FlowJo software (Tree Star Inc.).
Parasites and Immunization.
Female Anopheles stephensi mosquitoes infected with P. yoelii 17×NL strain were purchased from the New York University insectary. P. yoelii sporozoites were isolated from the salivary glands of infected A. stephensi mosquitoes 14 days after the mosquitoes had received an infectious blood meal. Sporozoites for immunization were attenuated after giving 15,000 rads by a gammairradiator. Mice were immunized with 5 × 10 4 to 1 × 10 5 irradiated sporozoites suspended in RPMI with 2% mouse sera by IV or intramuscular (IM) injection.
Depletion of T-Cell Subsets In
Vivo. MHC-I-K d -Tg mice were intraperitoneally injected with 250 g or 500 g of rat mAbs against CD4 (clone GK 1.5) or CD8 (clone YTS 169), respectively, on day −3 and day −1 prior to challenge with live P. yoelii sporozoites. The status of in vivo depletion of the corresponding T-cell subsets was assessed by flow cytometric assay, using anti-CD4 (clone RM4-5) and anti-CD8 (clone 53-6.7) mAbs.
Sporozoite Challenge and Assessment of Parasite Burden in the Liver.
Mice were challenged by IV injection of viable P. yoelii sporozoites with varied doses from 1 × 10 4 to 5 × 10 4 per mouse. Parasite burden in the liver was determined 42 h after the challenge by measuring parasite-specific 18S rRNA using a quantitative real-time reverse transcription-PCR method with the 7500 Fast Real-Time PCR System (Applied Biosystems). Parasite burden was described as a ratio of the absolute copy number of parasite-specific 18S rRNA to that of mouse GAPDH.
Statistics.
All of the statistical analyses were done using GraphPad Prism (version 5.03) (GraphPad Software Inc.). In the challenge experiment, parasite load in the liver was determined by a real-time RT-PCR. The values were then log-transformed and analyzed by 1-way ANOVA, followed by Dunnett's test. < 0.01 is considered statistically significant. The protection between MHC-I-K d -Tg mice and B6 mice against challenge of infectious P. yoelii sporozoites was evaluated after immunization with radiation-attenuated P. yoelii sporozoites (IrPySpz) by route of either IV or IM injections. As shown in Figure 2 , IrPySpz immunization resulted in a statistically significant reduction ( < 0.01) in parasite load via both IV and IM injections in the livers of MHC-I-K d -Tg mice. There was no such reduction in those of B6 mice in either IV or IM IrPySpz immunization routes. This is presumably because B6 mice lack K d molecules that can present PyCS-derived CD8+ T-cell epitope for the induction of protective antimalarial CD8+ T cells. The challenge results in Figure 2 also showed that IrPySpz immunization in MHC-I-K d -Tg mice via IV injection provided significantly more protection ( < 0.01) by way of liver stage parasite load reduction than the same immunization via IM injection. This finding corroborates the finding recently observed in humans showing that vaccination by IV of irradiated P. falciparum sporozoites induced protection [14] .
Results and Discussion
MHC-I-
In order to investigate which type of lymphocytes mediates the protective immunity against preerythrocytic stages of malaria, we depleted either CD4+ T cells or CD8+ T cells from MHC-K d -Tg mice immunized IM with a single dose of IrPySpz. As shown in Figure 3(a) , depletion of CD8+ T cells immunization. Naïve B6 mice and MHC-I-K d -Tg mice were also challenged as infection control. Parasite burden was described as a ratio of the absolute copy number of parasite-specific 18s rRNA to that of mouse GAPDH.
< 0.01 is considered statistically significant, whereas N.S. means "not significant" in However, it is still unclear to which extent a single immunizing dose of IrPySpz would induce protective immunity mediated by PyCS antigen-specific CD8+ T-cell response. Although a whole sporozoite consists of more than one thousand antigens, CS protein is shown to be a dominant antigen that can mediate the protective immunity against preerythrocytic stages of malaria. This was verified by using PyCS antigen transgenic mice (CS-Tg mice) that were tolerant to CS-T-cell epitopes, as PyCS-specific CD8+ T-cell response was not detected in the CS-Tg mice with BALB/c background upon IrPySpz immunization [18] . Therefore, in order to determine the contribution of PyCS antigen in overall protective antimalaria immunity induced by IrPySpz, we decided to cross MHC-I- 
